Chimeric Therapeutics Ltd (chm) Logo

Chimeric Therapeutics Ltd (CHM)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

Company Deep Dive

Chimeric Therapeutics, a clinical stage cell therapy company and the ASX leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM). CHM 1101 was developed by scientists at the City of Hope Medical Centre in California where it is currently being studied in a phase 1 clinical trial.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

Key Details
Established
2020
Treatments
2
Industry
Cancer Research
Headquartered
Carlton South, VIC
Primary Market
Cell Therapy
Updated: 01 Dec 2021

Why Invest In CHM?

The ASX leader in cell therapy with the most advanced pipeline

Two novel CAR T technologies from leading US medical institutions; City of Hope and the University of Pennsylvania

CHM 1101 (CLTX CAR T) phase 1 clinical trial underway in Glioblastoma at City of Hope

CHM 2101 (CDH17 CAR T) phase 1 clinical trial planned for 2022 in gastrointestinal cancers at the University of Pennsylvania

Highly attractive opportunities for further pipeline expansion

World class management team with extensive experience and expertise in cell therapy development

Cell therapy is the most active biotech investment space with intense big pharma interest and investment

People

Management Team

Jennifer Chow

Chief Executive Officer and Managing Director
Nov 2020 - Present

Jennifer is a cell therapy pioneer and expert with experience developing and commercializing FDA approved CAR T cell therapies, Abecma™, Breyzani™, Yescarta™ and Tecartus™. Jennifer also has experience leading the commercial development for more than 15 pipeline cell therapies.

Profile

Jennifer Chow

Chief Executive Officer and Managing Director

Nov 2020 - Present

Jennifer is a cell therapy pioneer and expert with experience developing and commercializing FDA approved CAR T cell therapies, Abecma™, Breyzani™, Yescarta™ and Tecartus™. Jennifer also has experience leading the commercial development for more than 15 pipeline cell therapies.

Jennifer joined Chimeric from Kite Pharmaceuticals where she was the Head of Global Marketing, Analytics and Commercial Operations and was responsible for optimizing the commercial development of all Kite pipeline therapies.

Prior to Kite, Jennifer was the Global Cell Therapy Commercial Lead at Celgene Corporation defining the global commercial strategy and operating model for Celgene cell therapies.

Jennifer has developed over 10 oncology therapeutics for launch and has more than 20 years’ experience in the biotech and pharmaceutical field.

Paul Hopper

Executive Chairman and Founder
Dec 2019 - Present

Paul is an inspired bioentrepreneur that has been instrumental in founding several successful biotechnology companies including Imugene, Viralytics, Prescient and now Chimeric Therapeutics.

Profile

Paul Hopper

Executive Chairman and Founder

Dec 2019 - Present

​​Paul is an inspired bioentrepreneur that has been instrumental in founding several successful biotechnology companies including Imugene, Viralytics, Prescient and now Chimeric Therapeutics.

Paul has over 25 years of experience in the biotech, healthcare and life sciences sectors serving as the Chairman, non-executive director or CEO of more than fourteen companies in the United States, Australia and Asia.

Paul has extensive experience fund raising in Australia, Asia, the US and Europe along with proven expertise in corporate governance, risk and strategy.

Paul was the former Chairman of Viralytics when it was acquired by Merck in 2018 and is currently on the board of 3 ASX listed companies.

Dr Syed Rizvi

Chief Medical Officer
Nov 2020 - Present

Syed has over 25 years of biotechnology and pharmaceutical industry experience leading global and US medical affairs and clinical teams.

Profile

Dr Syed Rizvi

Chief Medical Officer

Nov 2020 - Present

Syed has over 25 years of biotechnology and pharmaceutical industry experience leading global and US medical affairs and clinical teams.

Syed is a cell therapy pioneer with extensive development and commercialization experience. Dr Rizvi was one of the founding executive team at Legend Biotech where he was head of the CAR T program serving as VP Clinical Development and Medical Affairs and responsible for the development of the Ciltacabtagene Autoleucel BCMA CAR T program.

Prior to Legend, Syed was the head of global medical affairs for the CAR T and immuno-oncology programs at Celgene Corporation and the head of hematology, US medical affairs.

Dr Eliot Bourk

Vice President, Corporate and Business Development
Feb 2021 - Present

Eliot is a cell therapy expert with over 5 years leadership experience in the development and commercialization of cell therapies from early to late stage.

Profile

Dr Eliot Bourk

Vice President, Corporate and Business Development

Feb 2021 - Present

Eliot is a cell therapy expert with over 5 years leadership experience in the development and commercialization of cell therapies from early to late stage.

Eliot joined Chimeric from Kite Pharmaceuticals where he led early commercial strategy, responsible for the optimization of a portfolio of early-stage cell therapy pipeline assets and for guiding business development strategies and transactions.

Prior to joining Kite, Dr Bourk was a founding member of the cell therapy commercial team at Celgene Corporation and was the commercial lead for the development of next generation CAR T platforms.

Eliot has worked on the development and commercialization of the majority of the leading CAR T therapies including Abecma™, Breyzani™, Yescarta™ and Tecartus™.

Dr Li Ren

Vice President Technical Operations
Jun 2021 - Present

Li has nearly 20 years of experience developing and advancing cell therapy drug candidates from the pre-clinical stage through to commercial licensure.

Profile

Dr Li Ren

Vice President Technical Operations

Jun 2021 - Present

Li has nearly 20 years of experience developing and advancing cell therapy drug candidates from the pre-clinical stage through to commercial licensure.

Dr Ren has led the process and analytical development of multiple allogeneic & autologous cell therapy products over her career, including CAR T cells, TCR cells, NK cells and mesenchymal-like stem cells.

Dr Ren joined Chimeric from Bristol-Myers Squibb (BMS) where she most recently oversaw the technology transfers of Juno cell therapy pipeline products to BMS manufacturing facilities.

Over the course of her career Dr Ren has supported multiple IND submissions for pipeline products to enable clinical trials and designed and led process & analytical validation programs in support of commercial registration filing.

Board of Directors

Dr George Matcham

Non-Executive Director
Jun 2021 - Present

Dr George Matcham is cell therapy expert with over 30 years experience at Celgene Corporation where he championed the introduction of cellular immunotherapy and led the establishment of cell therapy and biologics technical development.

Profile

Dr George Matcham

Non-Executive Director

Jun 2021 - Present

Dr George Matcham is cell therapy expert with over 30 years experience at Celgene Corporation where he championed the introduction of cellular immunotherapy and led the establishment of cell therapy and biologics technical development.

George joined Celgene in 1988 when the company was a 30-person startup and after 3 decades of successful leadership retired in 2018 with the company shortly thereafter being acquired for $74B by Bristol-Myers Squibb (BMS).

Dr Matcham was vital to the growth of cell therapy at Celgene holding several leadership positions, including Chief Operations Officer of Celgene Cellular Therapeutics and Senior Vice President of CAR T CMC Development, where he oversaw clinical supply.

Dr Matcham holds a Ph.D in Biochemistry from Cardiff University and currently serves on the board and as an advisor at Instil Bio.

Dr Lesley Russell

Non-Executive Director

Dr Lesley Russell has over 25 years of international operational and leadership experience with established and emerging biotechnology companies including Amgen, Eli Lilly, Teva, and Cephalon.

Profile

Dr Lesley Russell

Non-Executive Director

Dr Lesley Russell has over 25 years of international operational and leadership experience with established and emerging biotechnology companies including Amgen, Eli Lilly, Teva, and Cephalon.

Dr Russell previously served as the Chief Medical Officer at Cephalon Inc. prior to its acquisition and as the Global Head of R&D at Teva Pharmaceuticals.

Dr Russell medical training and extensive experience in the area of hematology/oncology and has submitted more than a dozen NDAs or sNDAs to the US Food and Drug Administration over the course of her career.

Dr Russell currently serves as a Non-Executive Director of Enanta Pharmaceuticals and Imugene Ltd in addition to Chimeric Therapeutics.

Leslie Chong

Non-Executive Director
Sep 2020 - Present

Leslie began her career in oncology clinical development at GSK and Exelixis before taking a role at Genentech as a Senior Clinical Program Leader where she focused on therapies for brain cancer.

Profile

Leslie Chong

Non-Executive Director

Sep 2020 - Present

Leslie has over 20 years of experience in clinical development in oncology.

Leslie began her career in oncology clinical development at GSK and Exelixis before taking a role at Genentech as a Senior Clinical Program Leader where she focused on therapies for brain cancer.

Leslie has deep development experience with small molecules, immunotherapies, cancer vaccines, oncolytic viral therapies, epigenetics and monoclonal antibodies.

Ms Chong is currently the Chief Executive Officer and Managing Director of Imugene (ASX:IMU) and a Non-Executive Director of Cure Brain Cancer Foundation (CBCF).

Cindy Elkins

Non-Executive Director
Jan 2021 - Present

Cindy Elkins was Executive Vice President and Chief Information Officer at Juno Therapeutics, one of the pioneers in CAR T technology focused on blood cancers.

Profile

Cindy Elkins

Non-Executive Director

Jan 2021 - Present

Cindy Elkins was Executive Vice President and Chief Information Officer at Juno Therapeutics, one of the pioneers in CAR T technology focused on blood cancers.

After the acquisition of Juno, Cindy served as the Global Head CAR T Patient Experience at Celgene Corporation and Bristol-Myers Squibb (BMS) where she was responsible for connecting patients with their personalized therapy through world leading service and technology.

Prior to Juno, Ms. Elkins was Vice-President of Pharma Informatics at Genentech/Roche, where she was instrumental in ensuring all technology systems/processes were ready as soon as the FDA approved new medicines such as Zelboraf®, Gazyva®, Cotellic® and Tecentriq®.

Cindy currently serves as the Board Chair at the Foundation for Art and Healing in addition to as a non-executive director for Chimeric.

Treatments

Treatment

CHM 1101 (Chlorotoxin CAR T)

CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting domain.

  • CHM 1101 has been shown to more specifically and broadly target GBM cells than other immunotherapy targets like HER2, EGFR and IL13, through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2)

  • CCHM 1101 demonstrated excellent preclinical safety with no off tumour recognition of normal human or murine cells or tissues in preclinical models, consistent with the documented safety of administering CLTX containing agents in humans

  • CCHM 1101 demonstrated potent anti-tumour activity in vivo with significantly improved survival in mice

CHM 1101 is currently in clinical trials in patients with recurrent or progressive glioblastoma.

Learn More
Treatment

CHM 2101 (CDH17 CAR T)

CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target CDH17.

  • CHM 2101 was optimized over a decade of development to address the high unmet medical needs of patients with neuroendocrine tumours

  • A potent anti cancer antibody that optimally and specifically bound to neuroendocrine tumor cells was developed and through robust target validation, CDH17 was identified as the antigen target

  • The CDH17 CAR T was optimized as a 3rd generation construct with both CD28 and 41BB costimulatory domains

  • CHM 2101 preclinical evidence have demonstrated a unique potency for solid tumours with complete eradication of tumour cells with no relapse

Preclinical studies also demonstrated no toxicity to normal tissues.

Learn More

Key Milestones

Historical Milestones

Listed in Jan 2021, oversubscribed raise of $35m
Lead asset, CHM 1101, advancing in phase 1 clinical trial
Acquisition of CHM 2101, novel 3rd Gen CAR T

Future Milestones

Progress Development of CHM 2101, including filing for FDA IND
Initiate CHM 2101 Phase 1 Clinical Trial
Initiate CHM 1101 Phase 1 Basket Trial

Investment

Investors

Moreglade Pty Limited

BACKGROUND

Entity Controlled by Paul Hopper

CS Third Nominees Pty Limited

HSBC Custody Nominees

Capital Raises

ASX Listing
|Jan 2021

Chimeric Therapeutics Limited (‘CHM’) was admitted to the Official List of ASX Limited (‘ASX’) today, Friday, 15 January 2021.

Raised $35m
Offer Price $0.20
Notes

Documents

Transformative Portfolio Expansion Presentation

02 Dec 2021 | Presentation
PDF (6316.3 KB)

Annual Report

29 Sep 2021 | Annual Report
PDF (8096.5 KB)

Investor Newsletter

01 Sep 2021 | Newsletter
PDF (1796.6 KB)

Corporate Presentation

28 Jul 2021 | Presentation
PDF (15446.5 KB)

Add CHM to your Watchlist